NeuroMetrix, Inc. (NURO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Dec 2024)

FII

0.01%

Held by 1 FIIs

DII

98.18%

Held by 2 DIIs

Promoter

0.00%

How big is NeuroMetrix, Inc.?

22-Jun-2025

As of May 02, NeuroMetrix, Inc. has a market capitalization of 9.43 million, with net sales of 3.03 million and a net profit of -7.81 million over the last four quarters. As of December 2024, the company has shareholder's funds of 14.31 million and total assets of 15.32 million.

What does NeuroMetrix, Inc. do?

22-Jun-2025

NeuroMetrix, Inc. is a healthcare company specializing in bioelectrical and digital medicine for chronic health conditions, with recent net sales of $1 million and a market cap of $9.43 million. The company reported a net loss of $2 million in its latest quarter.

Should I buy, sell or hold NeuroMetrix, Inc.?

22-Jun-2025

Who are in the management team of NeuroMetrix, Inc.?

22-Jun-2025

As of March 2022, the management team of NeuroMetrix, Inc. is led by Dr. Shai Gozani, who is the Chairman, President, CEO, Secretary, and Director, alongside independent directors Dr. David Goodman, Ms. Nancy Katz, and Mr. David Van Avermaete.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Net Sales has grown by an annual rate of -20.04% over the last 5 years

The company has declared Negative results for the last 8 consecutive quarters

Risky - Not traded in last 10 days

Mojo Parameters

Stock DNA

Industry

Medical Specialties

Market cap

USD 9 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

408.36%

Debt Equity

-0.91

Return on Equity

-54.54%

Price to Book

0.66

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Dec 2024)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

6.26%

6 Months

14.5%

1 Year

3.15%

2 Years

234.31%

3 Years

-80.79%

4 Years

-80.92%

5 Years

-78.48%

NeuroMetrix, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-20.04%

EBIT Growth (5y)

-0.64%

EBIT to Interest (avg)

-5.01

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.91

Sales to Capital Employed (avg)

0.30

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

7.52%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.66

EV to EBIT

0.40

EV to EBITDA

0.42

EV to Capital Employed

-2.68

EV to Sales

-1.17

PEG Ratio

Dividend Yield

408.36%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-54.54%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Sideways

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (1.81%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 0.00% vs -25.00% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is -20.00% vs 0.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-1.70",
          "chgp": "-11.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-1.50",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,358.40%",
          "val2": "-2,966.10%",
          "chgp": "-39.23%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -49.15% vs -28.92% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -20.00% vs -47.73% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.00",
          "val2": "5.90",
          "chgp": "-49.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.50",
          "val2": "-7.10",
          "chgp": "-19.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.80",
          "val2": "-6.50",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,895.70%",
          "val2": "-1,211.80%",
          "chgp": "-168.39%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ

Dec'24

Sep'24

Change(%)

Net Sales

0.60

Operating Profit (PBDIT) excl Other Income

-1.90

-1.70

-11.76%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.80

-1.50

-20.00%

Operating Profit Margin (Excl OI)

-3,358.40%

-2,966.10%

-39.23%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2024 is 0.00% vs -25.00% in Sep 2024

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is -20.00% vs 0.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

3.00

5.90

-49.15%

Operating Profit (PBDIT) excl Other Income

-8.50

-7.10

-19.72%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.80

-6.50

-20.00%

Operating Profit Margin (Excl OI)

-2,895.70%

-1,211.80%

-168.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -49.15% vs -28.92% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -20.00% vs -47.73% in Dec 2023

All Annual Results

Company CV

About NeuroMetrix, Inc.

NeuroMetrix, Inc.

Medical Specialties

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Company Coordinates

Company Details

1000 Winter St , WALTHAM MA : 02451-1436

Tel: 1 781 8909989

http://www.neurometrix.com

Registrar Details

NeuroMetrix, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is NeuroMetrix, Inc.?

Watch in Real-Time

What does NeuroMetrix, Inc. do?

Should I buy, sell or hold NeuroMetrix, Inc.?

Who are in the management team of NeuroMetrix, Inc.?

MarketsMojo — Loved in India, Now Global

Dashboard

Poor Management Efficiency with a low ROE of 0%

Poor long term growth as Net Sales has grown by an annual rate of -20.04% over the last 5 years

The company has declared Negative results for the last 8 consecutive quarters

Risky - Not traded in last 10 days

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About NeuroMetrix, Inc.

Company Coordinates